Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs NetEase Inc (NTES) Price & Performance

Heron Therapeutics IncTrade
NetEase IncTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs NetEase Inc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while NetEase Inc trades at $123.35 (market cap $83.89B). The key difference: NetEase Inc is far larger — about 1323× Heron Therapeutics Inc's market cap, and NetEase Inc pays a 2.26% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXNTES
Market Cap
$63.41M$83.89B
Sector
HealthMedia
52-Week High
$1.49$159.34
52-Week Low
$0.32$109.26
Enterprise Value
$161.31M$60.18B
Dividend Yield
2.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

NetEase Inc

NTES trades at $132.22, up 1.43% today, with a bullish technical signal from moving averages and support near $131. The company reported Q1 2026 EPS of $2.53, beating estimates, and maintains strong profitability with a 29.84% net income margin. Recent news highlights upcoming Q2 2026 earnings on August 20, 2026, amid positive sentiment for Chinese tech stocks.

Outlook is positive with 82% analyst buy ratings and a 34.7% upside potential, though risks include earnings volatility and regulatory pressures. Revenue growth to $114.4B in 2026 and robust cash flow support valuation, but investors should monitor execution amid competitive and macroeconomic challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About NetEase Inc

NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).

Read more on NTES